RS63960B1 - Anti-met fab-fc za lečenje tumora i/ili metastaza - Google Patents

Anti-met fab-fc za lečenje tumora i/ili metastaza

Info

Publication number
RS63960B1
RS63960B1 RS20230107A RSP20230107A RS63960B1 RS 63960 B1 RS63960 B1 RS 63960B1 RS 20230107 A RS20230107 A RS 20230107A RS P20230107 A RSP20230107 A RS P20230107A RS 63960 B1 RS63960 B1 RS 63960B1
Authority
RS
Serbia
Prior art keywords
metastasis
tumor
treatment
met fab
fab
Prior art date
Application number
RS20230107A
Other languages
English (en)
Serbian (sr)
Inventor
Elisa Vigna
Cristina Basilico
Tiziana Crepaldi
Paolo Maria Comoglio
Original Assignee
Vertical Bio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertical Bio Ag filed Critical Vertical Bio Ag
Publication of RS63960B1 publication Critical patent/RS63960B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
RS20230107A 2018-10-09 2019-10-07 Anti-met fab-fc za lečenje tumora i/ili metastaza RS63960B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000009282A IT201800009282A1 (it) 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
PCT/EP2019/077116 WO2020074459A1 (fr) 2018-10-09 2019-10-07 Fab-fc anti-met pour le traitement d'une tumeur et/ou d'une métastase
EP19808675.3A EP3864050B1 (fr) 2018-10-09 2019-10-07 Fab-fc anti-met pour le traitement d'une tumeur et/ou d'une métastase

Publications (1)

Publication Number Publication Date
RS63960B1 true RS63960B1 (sr) 2023-02-28

Family

ID=65010823

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230107A RS63960B1 (sr) 2018-10-09 2019-10-07 Anti-met fab-fc za lečenje tumora i/ili metastaza

Country Status (21)

Country Link
US (1) US20210395372A1 (fr)
EP (2) EP3864050B1 (fr)
JP (1) JP7371093B2 (fr)
KR (1) KR20210075121A (fr)
CN (1) CN113330032A (fr)
AU (1) AU2019358417A1 (fr)
CA (1) CA3115582A1 (fr)
DK (1) DK3864050T3 (fr)
ES (1) ES2938714T3 (fr)
FI (1) FI3864050T3 (fr)
HR (1) HRP20230154T1 (fr)
HU (1) HUE060843T2 (fr)
IL (1) IL282033A (fr)
IT (1) IT201800009282A1 (fr)
LT (1) LT3864050T (fr)
PL (1) PL3864050T3 (fr)
PT (1) PT3864050T (fr)
RS (1) RS63960B1 (fr)
SG (1) SG11202103575RA (fr)
SI (1) SI3864050T1 (fr)
WO (1) WO2020074459A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063816A2 (fr) * 2003-12-19 2005-07-14 Genentech, Inc. Fragments d'anticorps univalents utiles en tant qu'agents therapeutiques
SI1981981T1 (sl) 2006-02-06 2012-01-31 Metheresis Translational Res Sa Anti-met monoklonalno protitelesce, njegovi fragmenti in vektorji, za zdravljenje tumorjev in ustrezni proizvodi
MX2008013705A (es) * 2006-04-28 2008-11-06 Esbatech Ag Anticuerpos que se enlazan al dominio extracelular de la cinasa de linfoma anaplastico del receptor tirosina cinasa.
CN106432503B (zh) * 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
US8362213B2 (en) * 2009-04-01 2013-01-29 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
WO2012135854A2 (fr) * 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Anticorps contre des peptides cytosoliques
MX2014002289A (es) * 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
RU2014124842A (ru) 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof

Also Published As

Publication number Publication date
LT3864050T (lt) 2023-03-27
EP3864050A1 (fr) 2021-08-18
SG11202103575RA (en) 2021-05-28
EP3864050B1 (fr) 2022-11-23
HUE060843T2 (hu) 2023-04-28
ES2938714T3 (es) 2023-04-14
AU2019358417A2 (en) 2021-06-24
FI3864050T3 (fi) 2023-03-14
JP7371093B2 (ja) 2023-10-30
DK3864050T3 (da) 2023-02-20
WO2020074459A1 (fr) 2020-04-16
US20210395372A1 (en) 2021-12-23
KR20210075121A (ko) 2021-06-22
EP4194469A1 (fr) 2023-06-14
HRP20230154T1 (hr) 2023-03-31
PL3864050T3 (pl) 2023-04-11
JP2022504392A (ja) 2022-01-13
CN113330032A (zh) 2021-08-31
IT201800009282A1 (it) 2020-04-09
SI3864050T1 (sl) 2023-03-31
IL282033A (en) 2021-05-31
AU2019358417A1 (en) 2021-05-27
CA3115582A1 (fr) 2020-04-16
PT3864050T (pt) 2023-01-18

Similar Documents

Publication Publication Date Title
IL269026A (en) Tumor treatment methods
IL267795A (en) Combined treatment for cancer
GB201804514D0 (en) Treatment of pyroptosis
GB201804255D0 (en) Macrophage-based therapy
IL282007A (en) Medicine to treat chronic cough
SG11202011117VA (en) Treatment of cancer
GB201819853D0 (en) Therapy
GB201900702D0 (en) Therapy
EP3706746A4 (fr) Polythérapie comprenant l'apatinib pour le traitement du cancer
IL281845A (en) Combined treatment for cancer
IL264589A (en) Combined treatment for pancreatic cancer
IL284162A (en) Integrated healing for cancer treatment
IL274314A (en) Tumor treatment methods
GB201804515D0 (en) Treatment of necroptosis
IL266993A (en) Combined therapy for cancer treatment
EP3579840C0 (fr) Traitement du cancer et suppression des métastases
IL277476A (en) A combination of anti-hepatocyte growth hormone receptor antibody and human epidermal hepatocyte growth hormone receptor for the treatment of cancerous tumor and/or metastasis
IL282033A (en) ANTI-MET FAB-FC for the treatment of tumor and/or metastases
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
IL253642A0 (en) Combined treatment for cancer
IL282157A (en) Compounds and their medicinal uses
GB201811902D0 (en) Treatment of hyperpigmentation
GB201820895D0 (en) Therapy